Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality. LEARN MORE NOVEL TECHNOLOGY NEW SOLUTION Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell cu...
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory (rel/ref) disease. A small minority of these can be cured wi
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 ...
Explore BPS Bioscience’s services for bispecific antibodies and BiTEs. Discover our solutions for developing and optimizing bispecific T-cell engager therapies.
BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to mitigate these limitations. Methods We constructed...
Oncologists Discuss Obstacles to Referring for CAR T-Cell Therapy in Multiple Myeloma Targeted Oncology Staff March 17th 2025 Article During a live event, John L. Wagner, MD, moderated a discussion on when to refer patients for CAR T-cell therapy and what challenges the referral pr...
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality. LEARN MORE NOVEL TECHNOLOGY NEW SOLUTION Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell cu...
“CD3 bispecifics would be considered direct competitors to CAR-T,” asserts Desjarlais. CAR T-cell therapies require weeks of preparation including cellular extraction from a patient, engineering in vitro, culturing, speculative dosing, and continued growth in vivo. In contrast, Desjarlais points...
EP: 7.Referral Process: CAR T-Cell Therapy EP: 8.CAR T: Impact of Recent Approvals on the Referral Process EP: 9.Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care EP: 10.Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM Video co...
Immunotherapies – such as checkpoint inhibitors and chimeric antigen receptor T-cells (CAR-Ts) – have transformed cancer treatment in the past decade, but the vast majority of patients still do not experience meaningful or durable benefits from these breakthrough therapies. While some may see that...